본문으로 건너뛰기
← 뒤로

Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization.

2/5 보강
Experimental hematology 📖 저널 OA 50% 2025: 1/2 OA 2026: 11/22 OA 2025~2026 2026 Vol.158() p. 105423 OA Hematopoietic Stem Cell Transplantat
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-05-02
OpenAlex 토픽 · Hematopoietic Stem Cell Transplantation Zebrafish Biomedical Research Applications Acute Myeloid Leukemia Research

Hiraki T, Yamamoto K, Chang YH, Nakayama C, Wunderlich M, Mizukawa B

📝 환자 설명용 한 줄

Hematopoietic stem cell (HSC)-targeted gene editing holds significant potential for treating hereditary hematopoietic disorders, yet the efficient and safe delivery of gene-editing tools into HSCs rem

이 논문을 인용하기

↓ .bib ↓ .ris
APA Takamasa Hiraki, Keita Yamamoto, et al. (2026). Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization.. Experimental hematology, 158, 105423. https://doi.org/10.1016/j.exphem.2026.105423
MLA Takamasa Hiraki, et al.. "Development of hematopoietic stem cell-targeted lipid nanoparticles through lipid composition optimization.." Experimental hematology, vol. 158, 2026, pp. 105423.
PMID 41887390 ↗

Abstract

Hematopoietic stem cell (HSC)-targeted gene editing holds significant potential for treating hereditary hematopoietic disorders, yet the efficient and safe delivery of gene-editing tools into HSCs remains a critical challenge. Lipid nanoparticles (LNPs) have emerged as a promising platform for nucleic acid delivery; however, achieving high transfection efficiency in HSCs remains challenging. In this study, we developed HSC-targeted LNPs by integrating Bayesian optimization with our functional amino lipids. The optimized LNPs exhibited markedly improved transfection efficiency while preserving cell viability, surpassing earlier formulations. Using these LNPs, we achieved ex vivo TP53 gene editing in cord blood (CB) CD34⁺ cells with up to 40% on-target editing efficiency. Additionally, one LNP demonstrated efficient RNA delivery into primary human monocytic leukemia cells. These results highlight the potential of machine learning-guided LNP design for advancing HSC-targeted therapies and underscore the promise of LNP-based gene-editing platforms to treat hereditary and malignant hematopoietic disorders.
🔓 OA PDF 열기